A total of 190 patients with acute ischemic stroke were identified for eligibility in a randomized , double-blind , placebo-controlled clinical trial , of which 150 patients allocated to either receiving NeuroAiD ( 80 cases ) or placebo ( 70 cases ) were analyzed after dropouts due to absence of baseline data , early death , or noncompliance .